generic Symbicort inhaler

Generic Symbicort Inhaler approved by FDA for asthma and COPD

Generic Symbicort has been approved by the U.S. Food and Drug Administration (FDA) on March 15, 2022, for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This is great news for those who suffer from these conditions, as Generic Symbicort is a much more affordable option than the brand name version. In this blog post, we will discuss the details of this announcement, as well as what it means for those who suffer from asthma or COPD.

What is Generic Symbicort inhaler?

Symbicort generic is a lower-cost version of the brand-name drug Symbicort and is just as effective. Symbicort is a combination of two drugs, budesonide and formoterol fumarate dihydrate. The inhaler is approved for 2 strengths: 160/4.5 mcg/actuation and 80/4.5 mcg/actuation. It’s used to treat asthma and COPD. Symbicort is a complex mixture of two drugs in a single inhaler. Budesonide is a corticosteroid that works by reducing inflammation in the lungs. Formoterol is a long-acting beta-agonist (LABA) that relaxes and opens air passages in the lungs, making it easier to breathe.

Generic drugs are cheaper than brand-name drugs because they don’t have to go through the costly process of research and development. The upcoming generic competition is great news for sufferers of asthma and COPD as the brand name Symbicort is a very expensive drug that has generated over $3.5 billion in sales for AstraZeneca for the 12 months ending in January 2021.

What does this approval mean for individuals with asthma and COPD?

The U.S. Food and Drug Administration (FDA) approval of Symbicort generic means that it is just as safe and effective as the brand-name drug. This is great news for those who suffer from asthma or chronic obstructive pulmonary disease (COPD), as Symbicort generic will be a more affordable option for long-term maintenance treatment.

This FDA approval of Generic Symbicort is great news for those who suffer from asthma or COPD, as it will provide a much more affordable option. Inhalers can be very expensive, and the brand name Symbicort inhaler can cost over $300. The generic version will be much cheaper, and will likely be available in late 2022.

The FDA granted approval of the first generic Symbicort inhaler to Viatris (formerly Mylan Pharmaceuticals, Inc.) and there will be other generic companies who will be authorized to start manufacturing generic Symbicort in the near future.

What are the next steps?

If you suffer from asthma or COPD, talk to your doctor about whether Generic Symbicort is right for you. You can also learn more by visiting the FDA’s website.

 

Also read

Featured image

Symbicort vs Advair

Having a good grasp of the medication you are taking and how it works will give you more confidence in managing you...

Read more
Featured image

Dulera vs Symbicort

There are many types of long-term asthma medications for controlling and preventing the symptoms of asthma such as ...

Read more
Featured image

Generic vs brand name drugs

There are often a lot of questions surrounding generic and brand-name medication. Are generics really as effective?...

Read more

Sources (2)

  1. FDA Approves First Generic of Symbicort to Treat Asthma and COPD

  2. Viatris - Press Release - Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva

The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.
NiceRx Logo

Your medication,
$49 per month

Get your brand name medication for only $49 per month through NiceRx.

Get Started